Skip to main content

Ghost Tree Capital, LLC

SEC CIK
0001595851
Latest filing
Nov 14, 2024

The latest 13F from Ghost Tree Capital, LLC covers Q3 2024 (filed Nov 14, 2024): 51 long positions worth $293.2M. The top 10 holdings make up 40.9% of the portfolio, and the largest is Biohaven Ltd at 5.9%. Livermore has 16 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2024

Share counts compared with Q2 2024: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

Full comparison
New
10
Est. +$50.2M
Added
16
Est. +$41.8M
Reduced
22
Est. −$75.8M
Sold out
18
Est. −$41.0M

Top 5 holdings

Share of this quarter's portfolio value

  1. Biohaven LtdG1110E907
    5.9%$17.4M
  2. SRPTSarepta Therapeutics, Inc.
    5.1%$15.0MHistory
  3. NVONovo Nordisk A S
    4.5%$13.1MHistory
  4. BPMCBlueprint Medicines Corp
    4.4%$12.9MHistory
  5. AXSMAxsome Therapeutics, Inc.
    4.1%$12.1MHistory

Biggest buys

New and added positions, by estimated amount bought

  1. Biohaven LtdG1110E907
    +$17.4MNew
  2. NVONovo Nordisk A S
    +$13.1MNewHistory
  3. BPMCBlueprint Medicines Corp
    +$9.25MAddedHistory
  4. SRPTSarepta Therapeutics, Inc.
    +$8.12MAddedHistory
  5. JANXJanux Therapeutics, Inc.
    +$6.36MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. Biohaven LtdG1110E907
    +5.94 pp0.0% → 5.9%
  2. NVONovo Nordisk A S
    +4.47 pp0.0% → 4.5%History
  3. BPMCBlueprint Medicines Corp
    +2.92 pp1.5% → 4.4%History
  4. JANXJanux Therapeutics, Inc.
    +2.21 pp0.7% → 2.9%History
  5. SRPTSarepta Therapeutics, Inc.
    +2.09 pp3.0% → 5.1%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. BHVNBiohaven Ltd.
    −$17.0MSold outHistory
  2. VRDNViridian Therapeutics, Inc.
    −$11.7MReducedHistory
  3. MLTXMoonLake Immunotherapeutics
    −$8.65MReducedHistory
  4. PCVXVaxcyte, Inc.
    −$8.00MReducedHistory
  5. SLNOSoleno Therapeutics Inc
    −$7.57MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. BHVNBiohaven Ltd.
    −5.92 pp5.9% → 0.0%History
  2. MLTXMoonLake Immunotherapeutics
    −2.38 pp4.6% → 2.2%History
  3. VRDNViridian Therapeutics, Inc.
    −2.08 pp2.7% → 0.6%History
  4. ALNYAlnylam Pharmaceuticals, Inc.
    −1.90 pp1.9% → 0.0%History
  5. SLNOSoleno Therapeutics Inc
    −1.68 pp4.3% → 2.6%History

Metrics

13F metrics for Q3 2024, computed only from the numbers in the filings. Definitions below.

Portfolio value
$293.2M
+$5.86M (+2.0%) vs. prior quarter
Positions
51
−8 vs. prior quarter
Top 10 concentration
40.9%
Top 10 as share of value
Turnover
31.7%
Q3 2024, one quarter
Average holding period
4.7 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

15 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $356.8M (Q1 2021)

Q1 2021: $356.8MQ2 2021: $319.8MQ3 2021: $303.3MQ4 2021: $261.1MQ1 2022: $201.8MQ2 2022: $145.5MQ3 2022: $244.9MQ4 2022: $234.2MQ1 2023: $264.3MQ2 2023: $277.1MQ3 2023: $206.5MQ4 2023: $173.7MQ1 2024: $311.1MQ2 2024: $287.4MQ3 2024: $293.2M
Q1 2021Q3 2024
13F filings of Ghost Tree Capital, LLC by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2024Nov 14, 202451$293.2MBiohaven LtdSRPTNVOvs. Q2 2024SEC
Q2 2024Aug 14, 202459$287.4MBHVNMLTXSLNOvs. Q1 2024SEC
Q1 2024May 15, 202465$311.1MAXSMSRPTBHVNvs. Q4 2023SEC
Q4 2023Feb 14, 202444$173.7MAXSMBHVNSRPTvs. Q3 2023SEC
Q3 2023Nov 14, 202358$206.5MMLTXKRYSMDGLvs. Q2 2023SEC
Q2 2023Aug 14, 202355$277.1MTGTXMLTXAKROvs. Q1 2023SEC
Q1 2023May 15, 202352$264.3MTGTXAMLXAXSMvs. Q4 2022SEC
Q4 2022Feb 14, 202335$234.2MRETAAXSMASNDvs. Q3 2022SEC
Q3 2022Nov 14, 202235$244.9MAPLSRETARLMDvs. Q2 2022SEC
Q2 2022Aug 15, 202229$145.5MFOLDAPLSSRPTvs. Q1 2022SEC
Q1 2022May 16, 202239$201.8MASNDCOGTAPLSvs. Q4 2021SEC
Q4 2021Feb 16, 202243$261.1MASNDAPLSCOGTvs. Q3 2021SEC
Q3 2021Nov 15, 202155$303.3MASNDIOVACLDXvs. Q2 2021SEC
Q2 2021Aug 11, 202149$319.8MRAPTASNDFATEvs. Q1 2021SEC
Q1 2021Aug 11, 2021Amended46$356.8MSNDXTrillium Therapeutics Inc.ASND–SEC